Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL
Proc Natl Acad Sci U S A. 2013 110 (35): 14372-7

PMID: 23940356 · PMCID: PMC3761610 · DOI:10.1073/pnas.1303204110

MeSH Terms (12)

Animals Antineoplastic Combined Chemotherapy Protocols Class I Phosphatidylinositol 3-Kinases Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition Genes, erbB-2 Lung Neoplasms Mammary Neoplasms, Experimental Mice Mice, Transgenic Mutation Phosphatidylinositol 3-Kinases

Connections (5)

This publication is referenced by other Labnodes entities: